4.6 Review

A systematic review of the asymmetric inheritance of cellular organelles in eukaryotes: A critique of basic science validity and imprecision

Journal

PLOS ONE
Volume 12, Issue 5, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0178645

Keywords

-

Funding

  1. Dutch Cancer Society Alpe d'HuZes/KWF program [UL2014-7058]

Ask authors/readers for more resources

We performed a systematic review to identify all original publications describing the asymmetric inheritance of cellular organelles in normal animal eukaryotic cells and to critique the validity and imprecision of the evidence. Searches were performed in Embase, MEDLINE and Pubmed up to November 2015. Screening of titles, abstracts and full papers was performed by two independent reviewers. Data extraction and validity were performed by one reviewer and checked by a second reviewer. Study quality was assessed using the SYRCLE risk of bias tool, for animal studies and by developing validity tools for the experimental model, organelle markers and imprecision. A narrative data synthesis was performed. We identified 31 studies (34 publications) of the asymmetric inheritance of organelles after mitotic or meiotic division. Studies for the asymmetric inheritance of centrosomes (n = 9); endosomes (n = 6), P granules (n = 4), the midbody (n = 3), mitochondria (n = 3), proteosomes (n = 2), spectrosomes (n = 2), cilia (n = 2) and endoplasmic reticulum (n = 2) were identified. Asymmetry was defined and quantified by variable methods. Assessment of the statistical reliability of the results indicated only two studies (7%) were judged to have low concern, the majority of studies (77`)/o) were 'unclear' and five (16`)/o) were judged to have 'high concerns'; the main reasons were low technical repeats (<10). Assessment of model validity indicated that the majority of studies (61`)/o) were judged to be valid, ten studies (32`)/o) were unclear and two studies (7%) were judged to have 'high concerns'; both described 'stem cells' without providing experimental evidence to confirm this (pluripotency and self-renewal). Assessment of marker validity indicated that no studies had low concern, most studies were unclear (96.5%), indicating there were insufficient details to judge if the markers were appropriate. One study had high concern for marker validity due to the contradictory results of two markers for the same organelle. For most studies the validity and imprecision of results could not be confirmed. In particular, data were limited due to a lack of reporting of interassay variability, sample size calculations, controls and functional validation of organelle markers. An evaluation of 16 systematic reviews containing cell assays found that only 50% reported adherence to PRISMA or ARRIVE reporting guidelines and 38% reported a formal risk of bias assessment. 44% of the reviews did not consider how relevant or valid the models were to the research question. 75% reviews did not consider how valid the markers were. 69% of reviews did not consider the impact of the statistical reliability of the results. Future systematic reviews in basic or preclinical research should ensure the rigorous reporting of the statistical reliability of the results in addition to the validity of the methods. Increased awareness of the importance of reporting guidelines and validation tools is needed for the scientific community.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medical Laboratory Technology

Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment

Shona Lang, Nigel Armstrong, Sohan Deshpande, Bram Ramaekers, Sabine Grimm, Shelley de Kock, Jos Kleijnen, Marie Westwood

ANNALS OF CLINICAL BIOCHEMISTRY (2019)

Article Endocrinology & Metabolism

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models

Nora M. Navone, Wytske M. van Weerden, Robert L. Vessella, Elizabeth D. Williams, Yuzhuo Wang, John T. Isaacs, Holly M. Nguyen, Zoran Culig, Gabri van der Pluijm, Cyril A. Rentsch, Rute B. Marques, Corrina M. A. de Ridder, Lukas Bubendorf, George N. Thalmann, William Nathaniel Brennen, Frederic R. Santer, Patrizia L. Moser, Peter Shepherd, Eleni Efstathiou, Hui Xue, Dong Lin, Jeroen Buijs, Tjalling Bosse, Anne Collins, Norman Maitland, Mark Buzza, Michelle Kouspou, Ariel Achtman, Renea A. Taylor, Gail Risbridger, Eva Corey

PROSTATE (2018)

Review Economics

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm, Nigel Armstrong, Bram L. T. Ramaekers, Xavier Pouwels, Shona Lang, Svenja Petersohn, Rob Riemsma, Gillian Worthy, Lisa Stirk, Janine Ross, Jos Kleijnen, Manuela A. Joore

PHARMACOECONOMICS (2019)

Article Biochemistry & Molecular Biology

Effects on prostate cancer cells of targeting RNA polymerase III

John L. Petrie, Caroline Swan, Richard M. Ingram, Fiona M. Frame, Anne T. Collins, Helene Dumay-Odelot, Martin Teichmann, Norman J. Maitland, Robert J. White

NUCLEIC ACIDS RESEARCH (2019)

Review Oncology

A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer

Shona H. Lang, Stephanie L. Swift, Heath White, Kate Misso, Jos Kleijnen, Ruben G. W. Quek

INTERNATIONAL JOURNAL OF ONCOLOGY (2019)

Review Public, Environmental & Occupational Health

A systematic review of the international prevalence of BRCA mutation in breast cancer

Nigel Armstrong, Steve Ryder, Carol Forbes, Janine Ross, Ruben G. W. Quek

CLINICAL EPIDEMIOLOGY (2019)

Review Oncology

Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review

Stephanie L. Swift, Shona H. Lang, Heath White, Kate Misso, Jos Kleijnen, Ruben G. W. Quek

FUTURE ONCOLOGY (2019)

Review Health Care Sciences & Services

Impact of tumor heterogeneity and tissue sampling for genetic mutation testing: a systematic review and post hoc analysis

Stephanie L. Swift, Steve Duffy, Shona H. Lang

JOURNAL OF CLINICAL EPIDEMIOLOGY (2020)

Review Neurosciences

Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease

Maria Joao Garcia, Regina Leadley, Shona Lang, Janine Ross, Elizabeth Vinand, Clive Ballard, Sandro Gsteiger

Summary: This study investigated the prevalence and treatment patterns of symptomatic treatment in early Alzheimer's disease (eAD). The results showed that some patients were using symptomatic treatment beyond approved indications, highlighting the need for new consensus guidelines to inform clinical practice.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Review Oncology

Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review

Robert Hettle, Adela Mihai, Shona H. Lang, Sophie Tatman, Stephanie L. Swift

Summary: This systematic review summarizes the real-world outcomes of abiraterone or enzalutamide in first-line metastatic castration-resistant prostate cancer. A total of 88 studies were included, with findings showing similar survival, safety, and economic outcomes across individual treatments. However, limited evidence suggests potential improvements in health-related quality of life with abiraterone. The review highlights the ongoing need for new regimens to address the poor outcomes in this patient population.

FUTURE ONCOLOGY (2023)

Review Medicine, General & Internal

Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis: a systematic review and meta-analysis

Stephanie Louise Swift, Thomas Puehler, Kate Misso, Shona Helen Lang, Carol Forbes, Jos Kleijnen, Marion Danner, Christian Kuhn, Assad Haneya, Hatim Seoudy, Jochen Cremer, Norbert Frey, Georg Lutter, Robert Wolff, Fueloep Scheibler, Kai Wehkamp, Derk Frank

Summary: The study compared the benefits and risks of TAVI and SAVR, finding that TAVI may reduce the risk of certain side effects while SAVR may reduce the risk of others. More data is needed to assess the long-term effects for low-risk patients, therefore every SAS patient should engage in SDM to make personalized decisions based on the benefits and risks of each treatment.

BMJ OPEN (2021)

Review Clinical Neurology

A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis

Gavin Giovannoni, Shona Lang, Robert Wolff, Steven Duffy, Robert Hyde, Elizabeth Kinter, Craig Wakeford, Maria Pia Sormani, Jos Kleijnen

NEUROLOGY AND THERAPY (2020)

Review Clinical Neurology

Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis

Maria Pia Sormani, Robert Wolff, Shona Lang, Steven Duffy, Robert Hyde, Elizabeth Kinter, Craig Wakeford, Gavin Giovannoni, Jos Kleijnen

NEUROLOGY AND THERAPY (2020)

Article Multidisciplinary Sciences

The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy

Robert I. Seed, Alberto J. Taurozzi, Daniel J. Wilcock, Giovanna Nappo, Holger H. H. Erb, Martin L. Read, Mark Gurney, Leanne K. Archer, Saburo Ito, Martin G. Rumsby, John L. Petrie, Aled Clayton, Norman J. Maitland, Anne T. Collins

SCIENTIFIC REPORTS (2019)

No Data Available